TY  - GEN
N2  - Identification of druggable mutations in Acute Myeloid Leukemia (AML), such as FLT3-ITD, has led to the development of targeted therapies capable of out-performing cytotoxic chemotherapy. Despite early survival benefits, most patients with FLT3-ITD AML on trial with the FLT3 inhibitor (FLT3i) gilteritinib still develop treatment resistance. Critical readout of response to FLT3i as measured by phospho-signaling is missing for the majority of these patients. Here, we validated an innovative approach to obtaining these signatures by leveraging the Smart BufferTM preservation system for peripheral blood (PB) specimens integrated with phospho-mass cytometry as part of the ongoing BeatAML Trial.
DO  - 10.6083/cn69m508w
DO  - DOI
AB  - Identification of druggable mutations in Acute Myeloid Leukemia (AML), such as FLT3-ITD, has led to the development of targeted therapies capable of out-performing cytotoxic chemotherapy. Despite early survival benefits, most patients with FLT3-ITD AML on trial with the FLT3 inhibitor (FLT3i) gilteritinib still develop treatment resistance. Critical readout of response to FLT3i as measured by phospho-signaling is missing for the majority of these patients. Here, we validated an innovative approach to obtaining these signatures by leveraging the Smart BufferTM preservation system for peripheral blood (PB) specimens integrated with phospho-mass cytometry as part of the ongoing BeatAML Trial.
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
T1  - Early phospho-signaling shifts in Smart BufferTM-preserved peripheral blood specimens in response to FLT3 inhibitor therapy
DA  - 2022
AU  - Newman, Matthew T.
AU  - Baker, Kristina
AU  - Joshi, Sunil K.
AU  - Pittsenbarger, Janet
AU  - Traer, Elie
AU  - Lind, Evan F.
AU  - Druker, Brian J.
L1  - https://digitalcollections.ohsu.edu/record/9569/files/Newman-Matthew-OHSU-ResearchWeek-2022.pdf
PB  - Oregon Health and Science University
PY  - 2022
ID  - 9569
L4  - https://digitalcollections.ohsu.edu/record/9569/files/Newman-Matthew-OHSU-ResearchWeek-2022.pdf
KW  - Neoplasms
KW  - Leukemia, Myeloid, Acute
KW  - beataml
KW  - phospho-signaling
KW  - cytof
KW  - gilteritinib
TI  - Early phospho-signaling shifts in Smart BufferTM-preserved peripheral blood specimens in response to FLT3 inhibitor therapy
Y1  - 2022
L2  - https://digitalcollections.ohsu.edu/record/9569/files/Newman-Matthew-OHSU-ResearchWeek-2022.pdf
LK  - https://digitalcollections.ohsu.edu/record/9569/files/Newman-Matthew-OHSU-ResearchWeek-2022.pdf
UR  - https://digitalcollections.ohsu.edu/record/9569/files/Newman-Matthew-OHSU-ResearchWeek-2022.pdf
ER  -